Board of Directors
John Garcia: Chairman, Independent Non-executive Director
Mr. Garcia was appointed to the Board of the Company in September 2007. With a 25-year career in the health products industry, he has been instrumental in the development and growth of several medical products and services companies. He served for more than ten years as president of Sulzermedica’s US$300m pacemaker business before it was acquired by Guidant in 1998. He also held sales and marketing management positions with FHP (a California HMO), Bio Science (a national reference lab) and Pharmaseal (a division of American Hospital Supply Corporation).
David Kravitz: Executive Director, Chief Executive Officer
Mr. Kravitz is an accomplished entrepreneur and inventor who has served in various senior executive, director and advisory positions throughout his career in life sciences. For over 20 years, his focus has been in the fields of trauma and transplantation medicine, women’s reproductive health, therapeutics adherence and regenerative medicine. He is a co-inventor of several dozen medical technology patents and has been a founder of medical technology companies including Organ Recovery Systems where he served as Chairman and CEO. In 2004, he was named in Fast Company magazine’s “Fast 50” list of global entrepreneurs and innovators. Mr. Kravitz is a co-founder of Lifeline Scientific and has served as the Company’s Chief Executive Officer since its inception.
Klaas de Boer: Non-executive Director
Mr. de Boer was appointed to the Board of the Company in September 2008. He has been operating at the intersection of technology, innovation and entrepreneurship in the US, Europe and Israel for the past 15 years. His career started with McKinsey & Company in Amsterdam in 1991. In 1997, he left consulting to set up a corporate venturing team for a former client, Baan Investment (later Vanenburg Group). Subsequently, he spent several years as an independent (angel) investor, advisor and interim manager in a range of entrepreneurial companies. In 2006, he joined the Entrepreneurs Fund, which he restructured, repositioned and now leads in his capacity as Managing Partner. Mr. de Boer sits on the boards of several other life sciences and medical technology companies.
Eric Swenden: Non-Executive Director
Mr. Swenden was appointed to the Board of the Company in 2003. He has had a long and successful career in finance and company management, having held positions on the boards of a broad array of public and private companies, including several drug companies, Vandemoortele Food Group and General Bank (Belgium’s largest bank before its merger with Fortis).
Dr. Andrew Clark: Senior Independent Non-executive Director
Dr. Clark was appointed to the Board of the Company in September 2007. He received his PhD in Neuroscience from St. Andrew’s University and was a post-doctoral research fellow in pharmacology at the University of Oxford. He worked in London as a biotech analyst at Baring Securities. In 1995, he co-founded Reabourne Ltd., an investment management business which focused on small capitalisation technology and biotechnology companies, where he acted as portfolio manager. He left Reabourne in 2003, following the sale of the business, and currently works as a consultant in the biotechnology field. He has held a number of non‑executive directorships of life science and investment companies.
Dr. Steven Mayer: Former Non-executive Director
Dr. Mayer was appointed to the Board of the Company in 2003 and, as announced on 6 March 2015, ceased to be a Director on 25 June 2015 as a consequence of his decision not to stand for re-election at the Company’s Annual General Meeting. A Doctor of Medicine and holder of a chemical engineering degree, he has a career of more than 20 years in diagnostics, devices and pharmaceuticals. He held several positions at Abbott Laboratories, including Director in the Abbott Diagnostics Division and Pharmaceutical Products Division, and gained experience in many areas including basic research and development, manufacturing, strategic planning, economics and outcomes research. Dr. Mayer has held advisory and scientific consultant roles at various medical companies.